Research programme: kinase inhibitors - Rottapharm BiotechAlternative Names: CR6970
Latest Information Update: 15 Oct 2015
At a glance
- Originator Rottapharm Madaus
- Developer Rottapharm Biotech
- Mechanism of Action Protein kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Osteoarthritis
Most Recent Events
- 15 Oct 2015 Early research in Osteoarthritis in Italy (unspecified route)